Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study.
Hamadani M, Collins GP, Caimi PF, Samaniego F, Spira A, Davies A, Radford J, Menne T, Karnad A, Zain JM, Fields P, Havenith K, Cruz HG, He S, Boni J, Feingold J, Wuerthner J, Horwitz S. Hamadani M, et al. Among authors: caimi pf. Lancet Haematol. 2021 Jun;8(6):e433-e445. doi: 10.1016/S2352-3026(21)00103-4. Lancet Haematol. 2021. PMID: 34048682 Free PMC article. Clinical Trial.
Editorial: Rising stars in hematology: 2022.
Gavriilaki E, de Lima M, Caimi PF, Arat M. Gavriilaki E, et al. Among authors: caimi pf. Front Med (Lausanne). 2023 Nov 22;10:1334125. doi: 10.3389/fmed.2023.1334125. eCollection 2023. Front Med (Lausanne). 2023. PMID: 38076238 Free PMC article. No abstract available.
Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomes.
Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Singh AD, Cooper BW, De Lima MJ, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, Pohlman BL, Hill BT, William BM. Starr AG, et al. Among authors: caimi pf. Br J Haematol. 2016 May;173(3):404-12. doi: 10.1111/bjh.13975. Epub 2016 Mar 8. Br J Haematol. 2016. PMID: 26953041 Free article.
Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era.
Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Cooper BW, De Lima MJ, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, Pohlman BL, Hill BT, William BM. Starr AG, et al. Among authors: caimi pf. Br J Haematol. 2016 Oct;175(2):275-280. doi: 10.1111/bjh.14228. Epub 2016 Jul 22. Br J Haematol. 2016. PMID: 27443247 Free article.
Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era.
Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Cooper BW, De Lima MJG, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, Pohlman BL, Hill BT, William BM. Starr AG, et al. Among authors: caimi pf. Hematology. 2017 Aug;22(7):405-411. doi: 10.1080/10245332.2017.1279842. Epub 2017 Jan 20. Hematology. 2017. PMID: 28105889 Free article.
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.
Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Caimi P, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Martin MG, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Snyder ED, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Dwyer MA, Sundar H. Wierda WG, et al. J Natl Compr Canc Netw. 2017 Mar;15(3):293-311. doi: 10.6004/jnccn.2017.0030. J Natl Compr Canc Netw. 2017. PMID: 28275031
Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study.
Kharfan-Dabaja MA, Raj R, Nikolaenko L, Ahmed S, Reddy N, Nathan S, Cherry M, El-Jurdi N, Obiozor C, Fenske TS, Song J, Muzzafar T, Ayala E, Savani B, Khawandanah M, Caimi PF, Hamadani M, Forman SJ, Hussaini M, de Lima M, Olteanu H, Shah B, Chavez JC, Al Malki M, Kumar A, Ganguly S. Kharfan-Dabaja MA, et al. Among authors: caimi pf. Biol Blood Marrow Transplant. 2018 Mar;24(3):486-493. doi: 10.1016/j.bbmt.2017.11.033. Epub 2017 Dec 7. Biol Blood Marrow Transplant. 2018. PMID: 29225164 Free article. Clinical Trial.
Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes.
Brammer JE, Chihara D, Poon LM, Caimi P, de Lima M, Ledesma C, Rondon G, Ciurea SO, Nieto Y, Fanale M, Dabaja B, Maziarz RT, Champlin RE, Hosing C, Oki Y. Brammer JE, et al. Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e41-e50. doi: 10.1016/j.clml.2017.10.001. Epub 2017 Oct 12. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29277360 Free PMC article.
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S, Lechowicz MJ, Gaur R, Lucas A, Melani C, Roschewski M, Steinberg SM, Jaffe ES, Kahl B, Friedberg JW, Little RF, Bartlett NL, Wilson WH. Dunleavy K, et al. Among authors: caimi pf. Lancet Haematol. 2018 Dec;5(12):e609-e617. doi: 10.1016/S2352-3026(18)30177-7. Lancet Haematol. 2018. PMID: 30501868 Free PMC article. Clinical Trial.
154 results